Sep 12, 2017 7:30am EDT Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001
Aug 08, 2017 6:05am EDT Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
Aug 03, 2017 8:05am EDT Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference
Jun 26, 2017 6:05am EDT Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
Jun 03, 2017 4:00pm EDT Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Jun 02, 2017 4:01pm EDT Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
Jun 01, 2017 7:05am EDT Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference
May 30, 2017 8:05am EDT Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference
May 16, 2017 7:05am EDT Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update
